News & Events

Learn about what's new with CMC Biologics

Kim Yang

Recent Posts by Kim Yang:

AGC Biologics Expands Capacity at Berkeley, California Facility

News

BERKELEY, Calif., March 6, 2018 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that their Berkeley, California facility is adding to its growing capacity with the addition of a 2000L single-use bioreactor (SUB).

AGC Biologics Holds Technical Seminar in South Korea

News

BOTHELL, Wash., Feb. 4, 2018 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company held its second bi-annual technical seminar in Seoul, South Korea, exclusively focused on early-phase development and manufacturing.

AGC Biologics to Hold Technical Seminar in Taiwan

News

BOTHELL, Wash., and BERKLEY, Calif., and COPENHAGEN, Denmark, and HEIDELBERG, Germany, and CHIBA, Japan, and YOKOHAMA, Japan, Jan. 21, 2018 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will hold a technical seminar in Taipei City, Taiwan, exclusively focused on early-phase development and manufacturing.

AGC Bioscience, Biomeva, and CMC Biologics to provide services under the brand AGC Biologics

News

BOTHELL, Wash., BERKLEY, Calif., COPENHAGEN, DK, HEIDELBERG, DE, CHIBA & YOKOHAMA, JAPAN ─ January 8, 2018 ─ AGC Biologics, a convergence of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics, announced today that effective January 8, 2018, the company will be integrated and newly branded as 
AGC Biologics.

Altor BioScience and CMC Biologics Announce Agreement for Manufacture and Validation of Altor’s IL-15 Superagonist Molecule, ALT-803, for use in Phase 3 Clinical Trials

News

BOTHELL, Washington and MIRAMAR, Florida, U.S.A., April 13, 2017—CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, and Altor BioScience Corporation (“Altor”), a leading developer of novel cytokine-based immunotherapeutics for cancer and infectious diseases, today announced that they have entered into a manufacturing agreement for the cGMP manufacturing of Altor’s ALT-803 molecule for use in Phase 3 clinical trials.

View or Download as a PDF  

AGC Asahi Glass Signs Agreement to Acquire CMC Biologics

News

CMC Biologics to continue to provide CDMO services to the biopharma marketplace

 

Bothell, WA, Copenhagen, Denmark, Berkeley, CA, and Tokyo, Japan– December 19, 2016 – CMC Biologics, a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins and AGC Asahi Glass (AGC), a world-leading manufacturer of glass, chemicals and high-tech materials, announced today that they have entered into a definitive agreement with CMC Biologics’ shareholders including Monitor Clipper Partners, European Equity Partners and Innoven Partenaires, by which AGC will acquire 100% of CMC Biologics’ shares. This acquisition is expected to close in January 2017. 

View or Download as a PDF  

Follow Us
Join us on LinkedIn Follow us on Twitter